Proposal of a scoring scale as a survival predictor in intracranial oligodendrogliomas

Journal of Neuro-Oncology

Volumn 79, Issue 2, 2006, Pages 159-168

  Hamlat, Abderrahmane ^a   Saikali, Stephan ^a   Chaperon, Jacques ^a   Carsin Nicol, Beatrice ^a   Calve, Michéle Le ^a   Lesimple, Thierry ^b   Ben Hassel, Mohamed ^b   Guegan, Yvon ^a  

^a PONTCHAILLOU UNIVERSITY HOSPITAL   (France)

^b CENTRE EUGÈNE MARQUIS   (France)

Author keywords

Grading; Intracranial tumor; Oligodendroglioma; Prognosis; Scale

Indexed keywords

ANTINEOPLASTIC AGENT;

ACCURACY; ADOLESCENT; ADULT; AGED; ARTICLE; BRAIN NECROSIS; BRAIN RADIOGRAPHY; CANCER CLASSIFICATION; CANCER GRADING; CANCER SURVIVAL; CHILD; CHROMOSOME ABERRATION; CLINICAL ASSESSMENT; CLINICAL FEATURE; CONTRAST RADIOGRAPHY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MITOSIS; NEUROSURGERY; OLIGODENDROGLIOMA; ONSET AGE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PROGNOSIS; RATING SCALE; SCORING SYSTEM; SURVIVAL TIME;

ADOLESCENT; ADULT; AGED; BRAIN NEOPLASMS; CHILD; CHILD, PRESCHOOL; CHROMOSOMES, HUMAN, PAIR 1; DIAGNOSIS-RELATED GROUPS; FEMALE; GENE DELETION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NECROSIS; NEOPLASM STAGING; OLIGODENDROGLIOMA; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; STATISTICS, NONPARAMETRIC; SURVIVAL ANALYSIS;

EID: 33748471509     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-005-9026-8     Document Type: Article

References (43)

1. Engelhard HH, Stelea A, Cochran EJ, Oligodendroglioma: Pathology and molecular biology Surg Neurol 58:111-117; 2002
2. Fortin D, Cairncross GJ, Hammond RR, Oligodendroglioma: An appraisal of recent data pertaining to diagnosis and treatment Neurosurgery45:1279-1291; 1999
3. Reifenberger G, Louis DN, Oligodendroglioma: Toward molecular definitions in diagnostic neuro-oncology. J Neuropath Exp Neurol 62:111-126; 2003
4. Daumas-Duport C, Varlet P, Tucker ML, Beuvon F, Cervera P, Chodkiewicz JP Oligodendrogliomas. Part I, patterns of growth, histological diagnosis, clinical and imaging correlations: A study of 153 cases J Neuro-Oncol 34:37-59; 1997
5. Deghani F, Schachenmayr W, Laun A, Korf HW, Prognostic implication of histopathological, immunohistochemical and clinical features of oligodendrogliomas: A study of 89 cases Acta Neuropathol95:493-504; 1998
6. Korshunov A, Golanov A, The prognostic significance of vascular endothelial growth factor (VEGF C-1) immunoexpression in oligodendroglioma: An analysis of 91 casesJ Neuro-Oncol48:13-19; 2000
7. Jeremic B, Shibamoto Y, Grujicic D, Milicic B, Stojanovic M, Nikolic N, Dagovic A, Aleksandrovic J, Combined treatment modality for anplastic oligodendroglioma: A phase II study J Neuro-Oncol43:179-185; 1999
8. Perry JR, Louis D, Cairncross JG, Current treatment of oligodendrogliomas Arch Neurol56:434-436; 1999
9. Shimizu KT, Tran LM, Mark RJ, Selch MT, Management of oligodendrogliomasRadiology186:569-572; 1993
10. Wallner KE, Gonzales M, Sheline GE, Treatment of oligodendrogliomas with or without postoperative irradiation J Neurosurg68:684-688; 1988
11. Celli P, Nofrone I, Palma L, Cantore G, Fortuna A, Cerebral oligodendroglioma: Prognostic factors and life history Neurosurgery35:1018-1025; 1994
12. Lindegaard KF, Mork SJ, Eide GE, Halvorsen TB, Hatlevoll R, Solgaard T, Dahl O, Ganz J, Statistical analysis of clinicopathological features, radiotherapy, and survival in 170 cases of oligodendrogliomaJ Neurosurg67:224-230; 1987
13. Mork SJ, Lindegaard KF, Halvorsen TB, Lehmann EH, Solgaard T, Hatlevoll R, Harvei S, Ganz J, Oligodendroglioma: Incidence and biological behaviour in a defined population J Neurosurg63:881-889; 1985
14. Shaw EG, Scheithauer BW, O'Fallon JR, Tazelaar HD, Davis DH, Oligodendrogliomas: The Mayo Clinic experience J Neurosurg76:428-434; 1992
15. Sun ZM, Genka S, Shitara N, Akanuma A, Takakura K, Factors possibly influencing the prognosis of oligodendroglioma Neurosurgery22:886-891; 1988
16. Van den Bent M, Chinot OL, Cairncross JG, Recent developments in the molecular characterization and treatment of oligodendroglial tumors Neuro-Oncol 5:128-138; 2003
17. Yeh SA, Lee TC, Chen HJ, Lui CC, Sun LM, Wang CJ, Huang EY, Treatment outcomes and prognostic factors of patients with supratentorial low-grade oligodendroglioma Int J Radiation Oncology Biol Phys54:1405-1409; 2002
18. Pirzkall A, Nelson SJ, McKnight TR, Takahashi MM, Li X, Graves EE, Verhey LJ,Wara WW, Larson DA, Sneed PK, Metabolic imaging of low-grade gliomas with three-dimensional magnetic resonancespectroscopy Int J Radiat Oncol Biol Phys53:1254-1264; 2002
19. Vaquero J, Zurita M, Morales C, Coca S, Prognostic significance of tumor-enhancement and angiogenesis in oligodendroglioma Acta Neurol Scand106:19-23; 2002
20. Leonardi MA, Lumenta CB, Oligodendrogliomas in the CT/MR-era Acta Neurochir (Wien)143:1195-1203; 2001
21. Ino Y, Betensky RA, Zlatescu MC, Sasaki H, Mcdonald DR, Stemmer-Rachamimov AO, Ramsay DA, Cairncross JG, Louis DN, Molecular subtypes of anaplastic oligodendroglioma: Implications for patient management at diagnosis Clin Cancer Res7:839-845; 2001
22. Diabira S, Rousselet MC, Gamelin E, Soulier P, Jadaud E, Menei P, PCV chemotherapy for oligodendroglioma: Response analyzed on T2 weighted-MRI J Neuro-Oncol55:45-50; 2001
23. Giammarile F, Cinotti LE, Jouvet A, Ramackers JM, Saint Pierre G, Thiesse P, Jouanneau E, Guyotat J, Pelissou-Guyotat I, Setiey A, Honnorat J, Le Bars D, Frappaz D, High and low grade oligodendroglioma(ODG): Correlation of amino-acid and glucose uptakes using PET and histological classifications J Neuro-Oncol68:263-274; 2004
24. Alvord EC Jr, Is necrosis helpful in the grading of gliomas? Editorial opinion. J Neuropathol Exp Neurol 51:127-132; 1992
25. Daumas-Duport C, Tucker ML, Kolles H, Cervera P, Beuvon F, Varlet P, Udo N, Koziak M, Chodkiewicz JP Part II. A new grading system based on morphological and imaging criteria J Neuro-Oncol34:61-78; 1997
26. Kros JM, Troost D, Eden CG, Van Der Werf AJM, Uylings HBM, Oligodendroglioma: A comparison of two grading systemsCancer61:2251-2259; 1988
27. Prayson RA, DS Mohan, Song P, Suh JH, Clinocopathologic study of forty-four histologically pure supratentorial oligodendrogliomas Ann Diagn Pathol 4:218-227; 2000
28. Vaquero J, Zurita M, Coca S, Oya S, Morales C, Prognostic significances of clinical and angiogenesis-related factors in low-grade oligodendrogliomasSurg Neurol54:229-234; 2000
29. Bigner SH, Matthews MR, Rasheed BKA, Wiltshire RN, Friedman HS, Friedman AH, Stenzel TT, Dawes DM, McLendon RE, Bigner DD, Molecular genetic aspects of oligodendrogliomas including analysis by comparative genomic hybridizationAm J Pathol155:375-386; 1999
30. Cairncross JG, Ueki K, Zlatescu MC, Lisle DK, Finkelstein DM, Hammond RR, Silver JS, Stark PC, Macdonald DR, Ino Y, Ramsay DA, Louis DN, Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas J Natl Cancer Inst90:1473-1479; 1998
31. Nutt CL, Mani DR, Betensky RA, Tamayo P, Cairncross JG, Ladd C, Pohl U, Hartmann C, McLaughlin ME, Batchelor TT, Black PM, Von Deimling A, Pomeroy SL, Golub TR, Louis D, Gene expression-based classification of malignant gliomas correlates better with survival than histological classification Cancer Res63:1602-1607; 2003
32. Jeuken JWM, Sprenger SHE, Wermeer H, Kapelle AC, Boerman RH, Wesseling P, Chromosomal imbalances in primary oligodendroglial tumors and their recurrences: Clues about malignant progression detected using comparative genomic hybridization J Neurosurg96:559-564; 2002
33. Watson MA, Perry A, Budhjara V, Hicks C, Shannon WD, Rich KM, Gene expression profiling with oligonucleotide microarrays distinguishes World Heath Organization grade of oligodendrogliomas Cancer Res61:1825-1829; 2001
34. Nigro JM, Takahashi MA, Ginzinger DG, Law M, Passe S, Jenkins RB, Aldape K, Detection of 1p and 19q loss in oligodendroglioma by quantitative microsatellite analysis, a real time quantitative polymerase chain reaction assay Am J Pathol158:1253-1262; 2001
35. Smith JS, Perry A, Borell TJ, Lee HK, O'Fallon J, Hosek SM, Kimmel D, Yates A, Burger PC, Scheithauer BW, Jenkins RB, Alterations of chromosome arms 1p and 19q as predictors survival in oligodendrogliomas, astrocytomas and mixed oligoastrocytomas J Clin Oncol18:636-645; 2000
36. Zlatescu MC, TehraniYazdi R, Sasaki H, Megyesi JF, Betensky RA, Louis DN, Cairncross JG, Tumor location and growth pattern correlate with genetic signature in oligodendroglial neoplasmsCancer Res61:6713-6715; 2001
37. Kleihues P, Louis DN, Scheithauer BW, Rorke L, Reifenberger G, Burger PC, Cavenee WK, The WHO classification of tumors of the nervous system J Neuropathol Exp Neurol61:215-225; 2002
38. Mark HFL, Fluorescence in situ hybridization as an adjunct to conventional cytogenetics Ann Clin Lab Sci24:153-163; 1994
39. Smith JS, Alderete B, Minn Y, Borell TJ, Perry A, Mohapatra G, Hosek SM, Kimmel D, O'Fallon J, Yates A, Feuerstein BG, Burger PC, Scheithauer BW, Jenkins RB, Localization of common deletion regions on 1p and 19q in human gliomas and their association with histological subtype Oncogene18: 4144-4152; 1999
40. Smith MT, Ludwig CL, Godfrey AD, Armbrustmacher VW, Grading oligodendrogliomas Cancer52: 2107-2114; 1983
41. Coons SW, Johnson PC, Scheithauer BW, Yates AJ, Pearl DK, Improving diagnostic accuracy and interobserver concordance in the classification and grading of primary gliomas Cancer79:1381-1393; 1997
42. Prayson RA, Castilla EA, Hembury TA, Liu W, Noga CM, Prok AL, Interobserver variability in determining MIB-1 labeling indices in oligodendroglioma Ann Diagn Pathol7:9-13; 2003
43. Kearney L Molecular cytogenetics Best Practice & ResearchClin Haematol 14:645-668; 2001